Vivos Therapeutics (VVOS) Stock Forecast & Price Target

Vivos Therapeutics Inc. demonstrates a strong financial trajectory, with Q3 FY25 revenues reaching $6.8 million, reflecting a remarkable 76% year-over-year increase and a 78% sequential rise, driven primarily by the successful integration of the SCN model. The company has also seen service revenue more than double to $4.6 million, bolstered by significant contributions from sleep testing and treatment-center revenues associated with SCN, indicating robust demand for their innovative approach to addressing sleep-disordered breathing. Furthermore, the positive clinical outcomes, with a substantial percentage of patients experiencing marked improvement, coupled with the anticipated growth in the Asia Pacific region due to increased healthcare infrastructure and awareness, support a favorable outlook for the company's future revenue expansion.

Vivos Therapeutics Inc. experienced a year-over-year decline in revenue of 9% for the first half of 2025, with Q2 revenues of $3.8 million falling short of estimates due to a transition to direct sleep center management, despite a quarterly rebound of 27% from the previous quarter. This transition has also contributed to reduced gross margins, which dropped to 55% as a result of discounting and changes in the product mix. The company has a persistent history of operating losses, negative cash flow, and significant accumulated deficits, raising concerns over its ability to secure capital, acquire new customers, and achieve sustainable profitability.